slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 66,421-66,450
Pages 3,679
Rows per page 30
Component
66,421-66,450 of 110,355
22
Includes a pie chart for portfolio breakout and a bar chart for yield/spread trends.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Key Performance IndicatorsLoop · Zoom In1 hit
25
Includes footnotes regarding tax impact and tax-exempt income calculations.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Appendix1 hit
26
Includes footnotes explaining tax impact calculations and specific exclusions.CrossFirst Bankshares | Results Presentation Deck | 28 slides · CrossFirst Bankshares
Conference presentation Investor relations Beat · Appendix1 hit
09
Includes logos for Heights Finance and 1st Heritage Credit.CURO Group Holdings | Credit Presentation Deck | 23 slides · CURO
Pitch deck Investor relations 1 hit
10
Includes logos for CashMoney and LendDirect. Data is illustrative and normalized for pandemic impacts.CURO Group Holdings | Credit Presentation Deck | 23 slides · CURO
Pitch deck Investor relations 1 hit
11
Includes a list of merchant partner logos at the bottom.CURO Group Holdings | Credit Presentation Deck | 23 slides · CURO
Pitch deck Investor relations 1 hit
19
The slide uses a bar chart to segment the US population by FICO score, with a dashed box highlighting the target customer segment.CURO Group Holdings | Credit Presentation Deck | 23 slides · CURO
Pitch deck Investor relations 1 hit
04
Uses a contrast-based argument: low research investment vs. high market performance.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Loop · Golden Circle1 hit
05
Uses a comparative framework to validate market potential by citing peak sales of existing products.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Market Size1 hit
07
The slide uses a numbered list to outline the investment thesis and a callout box for specific 2022 milestones.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
08
The slide uses a horizontal bar chart format to represent clinical trial stages for various assets.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
11
The slide uses a structured grid layout to present seven distinct product development programs.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
12
The slide uses a flow-like diagram to connect internal strengths to external market trends, supported by a list of recent industry transactions.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
15
The slide uses a callout box to summarize the upcoming milestones for the company's pipeline.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
17
The slide uses a three-row layout to contrast the problem, current limitations, and the proposed solution.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
19
The slide highlights a key business development milestone involving a $10M upfront payment and potential $182.5M in milestones.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
20
Standard pharmaceutical ISI (Important Safety Information) slide.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
21
This slide provides regulatory/clinical disclosure information regarding special populations.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
23
The slide uses a combination of a demographic projection chart and a hub-and-spoke diagram of successful products to establish market scale.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
24
Uses a tree-like decomposition to show the total addressable market and its sub-segments.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
26
The slide uses a comparison framework to map user needs to product capabilities.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution1 hit
27
Highlights the validation of the product by a major industry player (Bayer) and the financial terms of the deal.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
28
Includes a testimonial/quote from a partner at the bottom.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
29
Includes specific clinical data points from a Postcoital Test (PCT) study.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
32
The slide uses a two-part structure: global meta-analysis data followed by US-specific market sizing.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
33
The slide uses a bulleted list to define the product profile and concludes with a strong market gap statement regarding FSAD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
36
Includes both tabular pharmacokinetic data and a line chart showing plasma concentration over time.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit